Oramed Pharmaceuticals Inc. Files 8-K for Material Agreement
Ticker: ORMP · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.012, $11.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k
Related Tickers: ORAM
TL;DR
ORAM filed an 8-K on 9/23 for a material definitive agreement.
AI Summary
On September 23, 2024, Oramed Pharmaceuticals Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in New York, filed an 8-K report detailing this agreement.
Why It Matters
This filing indicates a significant development for Oramed Pharmaceuticals Inc., potentially impacting its business operations and future strategies.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant business changes, risks, or opportunities that are not yet fully understood.
Key Players & Entities
- ORAMED PHARMACEUTICALS INC. (company) — Registrant
- September 23, 2024 (date) — Date of earliest event reported
- 1185 Avenue of the Americas, Third Floor, New York, New York 10036 (address) — Principal Executive Offices
- 001-35813 (company_id) — SEC File Number
FAQ
What is the nature of the material definitive agreement entered into by Oramed Pharmaceuticals Inc. on September 23, 2024?
The filing does not specify the details of the material definitive agreement, only that one was entered into on September 23, 2024.
What is Oramed Pharmaceuticals Inc.'s SEC file number?
Oramed Pharmaceuticals Inc.'s SEC file number is 001-35813.
Where are Oramed Pharmaceuticals Inc.'s principal executive offices located?
Oramed Pharmaceuticals Inc.'s principal executive offices are located at 1185 Avenue of the Americas, Third Floor, New York, New York 10036.
When was the 8-K report filed by Oramed Pharmaceuticals Inc.?
The 8-K report was filed on September 26, 2024, with the earliest event reported being September 23, 2024.
What is Oramed Pharmaceuticals Inc.'s state of incorporation?
Oramed Pharmaceuticals Inc. is incorporated in Delaware.
Filing Stats: 1,123 words · 4 min read · ~4 pages · Grade level 14.9 · Accepted 2024-09-26 16:05:37
Key Financial Figures
- $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Te
- $11.5 million — n a total amount of up to approximately $11.5 million that will be paid over the term of the
Filing Documents
- ea0215648-8k_oramed.htm (8-K) — 29KB
- ea021564801ex10-1_oramed.htm (EX-10.1) — 65KB
- 0001213900-24-082237.txt ( ) — 283KB
- ormp-20240923.xsd (EX-101.SCH) — 3KB
- ormp-20240923_lab.xml (EX-101.LAB) — 33KB
- ormp-20240923_pre.xml (EX-101.PRE) — 22KB
- ea0215648-8k_oramed_htm.xml (XML) — 4KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On September 23, 2024, Oramed Ltd. (the "Subsidiary"), a wholly-owned subsidiary of Oramed Pharmaceuticals Inc. (the "Company"), entered into a Master Services Agreement (the "Agreement") with InClin, Inc. ("InClin"), to retain InClin as a clinical research organization. The services covered by the Agreement may include strategic planning, expert consultation, statistical programming and analysis, data processing, data management, regulatory, clerical, project management, medical writing and other research and development services requested by the Subsidiary and agreed to by InClin for the Subsidiary's planned upcoming Phase 3 clinical trial. The trial will be conducted under an Investigational New Drug application with the U.S. Food and Drug Administration and is designed to assess the safety and evaluate the efficacy of ORMD-0801 on approximately 300 type 2 diabetic patients. The Subsidiary can terminate the Agreement with or without cause upon 30 days written notice to InClin. Either party can terminate the Agreement upon 30 days written notice to the other party in case of a breach, and the party fails to cure such breach within 30 days following the date of such notice. As consideration for its services, the Subsidiary will pay InClin a total amount of up to approximately $11.5 million that will be paid over the term of the engagement and based on the number of hours performed by InClin per month. The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 1.01 and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 10.1 Master Services Agreement dated September 23, 2024, between Oramed Ltd. and InClin, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO September 26, 2024 2